Autologous cultured chondrocytes
- First approval year
- 2009
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Unknown
- Drug name
- Autologous cultured chondrocytes
- maci
- Maci
- autologous cultured chondrocytes
- Autologous cultured chondrocytes
- carticel
- Carticel
- characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
- CHARACTERISED VIABLE AUTOLOGOUS CARTILAGE CELLS EXPANDED EX VIVO EXPRESSING SPECIFIC MARKER PROTEINS
- CHARACTERISED VIABLE AUTOLOGOUS CARTILAGE CELLS EXPANDED EX VIVO EXPRESSING SPECIFIC MARKER PROTEINS [EMA EPAR]
- characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins ema epar
- chondrocelect
- CHONDROCELECT
- maci
- Maci
- MACI
- matrix applied characterised autologous cultured chondrocytes
- Matrix-applied characterised autologous cultured chondrocytes
- ChEMBL ID
- CHEMBL5315092
- FDA ingredient codes (UNII)
- D5P3K3V822
- First in class
- No
- Orphan designation
- No
- Condition
- Fractures, Cartilage
- Highest recorded phase
- 4
- Subject identifier
- D050724
- Condition
- Cartilage Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005802
- Subject identifier
- D002357
- Condition identifier
- EFO_0005802
- Condition identifier
- EFO_0005802
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0003816
- Condition identifier
- MONDO_0003816
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004355
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005178
- Highest recorded phase
- 1
- Event
- adhesion
- Reports
- 6
- Reporting signal score
- 25.8467
- Event
- arthralgia
- Reports
- 42
- Reporting signal score
- 40.6385
- Event
- arthrofibrosis
- Reports
- 12
- Reporting signal score
- 87.2885
- Event
- arthropathy
- Reports
- 13
- Reporting signal score
- 19.6992
- Event
- chondromalacia
- Reports
- 25
- Reporting signal score
- 174.796
- Event
- chondropathy
- Reports
- 17
- Reporting signal score
- 82.9315
- Event
- chondroplasty
- Reports
- 5
- Reporting signal score
- 35.2955
- Event
- exostosis
- Reports
- 37
- Reporting signal score
- 165.489
- Event
- failure of implant
- Reports
- 32
- Reporting signal score
- 238.702
- Event
- graft complication
- Reports
- 55
- Reporting signal score
- 395.013
- Event
- graft delamination
- Reports
- 21
- Reporting signal score
- 178.842
- Event
- graft overgrowth
- Reports
- 15
- Reporting signal score
- 126.438
- Event
- hypertrophy
- Reports
- 15
- Reporting signal score
- 88.8862
- Event
- inadequate osteointegration
- Reports
- 4
- Reporting signal score
- 30.4916
- Event
- joint adhesion
- Reports
- 12
- Reporting signal score
- 91.6076
- Event
- joint effusion
- Reports
- 10
- Reporting signal score
- 30.2284
- Event
- joint lock
- Reports
- 8
- Reporting signal score
- 32.61
- Event
- joint swelling
- Reports
- 17
- Reporting signal score
- 19.6525
- Event
- localised osteoarthritis
- Reports
- 10
- Reporting signal score
- 65.8771
- Event
- loose body in joint
- Reports
- 22
- Reporting signal score
- 148.835
- Event
- meniscus lesion
- Reports
- 11
- Reporting signal score
- 50.1617
- Event
- osteoarthritis
- Reports
- 11
- Reporting signal score
- 18.3211
- Event
- patellofemoral pain syndrome
- Reports
- 11
- Reporting signal score
- 60.6097
- Event
- post procedural complication
- Reports
- 15
- Reporting signal score
- 40.0684
- Event
- post procedural pain
- Reports
- 7
- Reporting signal score
- 43.2063
And 5 more, listed on the interactive page.
- Implant should be cut to the size and shape of the defect
- Single-use implant, multiple implants may be used if more than one defect
- Use during surgical implantation only
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (73)
- A Clinical Trial Testing Root Coverage With Acellular Dermal Matrix in Thin and Thick Gingival Biotypes
- A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.
- A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs
- A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP
- A Study of Different Injectable Formulations of LY3375880 in Healthy Participants
- A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
- A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
- A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects
- A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1
- A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
- An Observational, Prospective Study of Patients With Chondral and/or Osteochondral Defects of the Knee Treated With NAMIC
- Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
- Autologous Cell-derived Tissue Engineered Cartilage for Repairing Articular Cartilage Lesions
- Biologicals in Management of Intra-Bony Defects
- Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal® Application Total Hip Arthroplasty
- Bone Defects Reconstruction After Dentigerous Cyst Enucleation With Autogenous Demineralized Dentin Matrix- ADDM and Advanced Platelet-Rich Fibrin- A-PRF.
- Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial
- Clinical and Radiographic Evaluation of Three Biomimetic Materials in Pulp Therapy of Immature Young Permanent Teeth "A Randomized Controlled Clinical Trial"
- Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease
- Clinical, Radiographic and Volumetric Evaluation of the Entire Papilla Preservation Technique With and Without Connective Tissue Graft in the Treatment of Periodontal Intraosseous Defects.
Approved for (1)
- Chondromalacia
In development for (1)
- Childhood leukemia Phase 3
Other linked conditions (1)
- Articular cartilage disorder